Thyroid eye disease (TED), also known as thyroid-associated ophthalmopathy or Graves’ orbitopathy (GO), in which the immune system mistakenly targets tissues around the eyes. This results in inflammation and swelling of the eye muscles, fat, and connective tissue, causing symptoms such as bulging eyes (proptosis), double vision (diplopia), eye pain, dryness, and in severe cases, vision loss. In the active phase, newer targeted therapies like TEPEZZA (teprotumumab), a monoclonal antibody that inhibits IGF-1R, have shown significant effectiveness in reducing proptosis and disease activity. Other molecular targets, such as TSHR, IL-6/IL-6R, FcRn, are also actively targeted in therapeutic R&D. PharmaLegacy has pioneered in this area with development of several exclusive models to suit different MoA and timelines.